Xipere FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 26, 2021.
FDA Approved: Yes (First approved October 22, 2021)
Brand name: Xipere
Generic name: triamcinolone acetonide
Dosage form: Injection
Company: Clearside Biomedical, Inc.
Treatment for: Macular Edema, Uveitis
Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.
- Corticosteroids such as triamcinolone acetonide are the standard of care in uveitis and are effective at treating the inflammatory aspect of ocular disease. Approximately one-third of uveitis patients develop uveitic macular edema, a build-up of fluid in the macula which causes retinal swelling and distorted vision, and may lead to permanent vision loss.
- Xipere is administered via the SCS Microinjector® to provide targeted delivery into the suprachoroidal space in the back of the eye. Targeted delivery means the drug has the potential to act for a longer period of time, while minimizing harm to the surrounding healthy parts of the eye.
- Common adverse reactions include elevated intraocular pressure and eye pain.
Development timeline for Xipere
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
